Collectively, our study highlights IL‐1β as an important immune therapy target in advanced PCa and proposes that anti‐IL‐1β antibody together with ADT and ICB is a new attractive combination therapy strategy for PCa. Here, IL1B is linked to posterior cortical atrophy.